Rutgers Health/Robert Wood Johnson Medical School
Obstetrics and Gynecology residency · New Brunswick, NJ · Program website
This program's roster hasn't been collected yet, so there's no list of its own faculty and papers. Below is Rutgers Health's research in obstetrics and gynecology, which the program shares with other departments and affiliated hospitals.
About Rutgers Healthinstitution-wide obstetrics and gynecology research
Obstetrics and Gynecology publications from Rutgers Health and affiliated institutions, since 2022. Updated 2026-11-06; refreshed daily.
30
works per year
40th of 81 obstetrics and gynecology residency programs
+20.4%
2-year growth
22nd of 80 obstetrics and gynecology residency programs
17.0%
in top 10% of field (works before 2025)
56th of 67 obstetrics and gynecology residency programs
30.7%
cited above world average
61st of 67 obstetrics and gynecology residency programs
Works per year · * 2026 so far
Obstetrics and Gynecology · 90Reproductive Medicine · 52
Obstetrics and Gynecology research topics at Rutgers Health
Papers in the window; each links to the list on OpenAlex.
- Endometrial and Cervical Cancer Treatments 38
- Ovarian cancer diagnosis and treatment 27
- Pregnancy and preeclampsia studies 19
- Uterine Myomas and Treatments 12
- Ovarian function and disorders 10
- Reproductive Health and Technologies 8
- Gynecological conditions and treatments 8
- Maternal and Perinatal Health Interventions 5
Most cited at Rutgers Health since 2024
All obstetrics and gynecology papers there on OpenAlex
- Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trialRamez Nassef Eskander et al. · Nature Medicine · 2025 · PubMed · cited 93
- Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trialAlexander Babatunde Olawaiye et al. · The Lancet · 2025 · PubMed · cited 69
- Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trialDomenica Lorusso et al. · The Lancet · 2026 · PubMed · cited 28
- Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 studyAntonio González-Martı́n et al. · Gynecologic Oncology · 2024 · PubMed · cited 27
- Management of Postpartum Preeclampsia and Hypertensive Disorders (MOPP)Emily B. Rosenfeld et al. · JACC Advances · 2025 · PubMed · cited 18
- Endometriosis and menopausal health: An EMAS clinical guideCemal Tamer Erel et al. · Maturitas · 2025 · PubMed · cited 17
- Obesity Epidemic and Its Impact on Female Fertility: Current Understanding and Future DirectionsRadhika Malhotra et al. · Cureus · 2025 · PubMed · cited 13
- Embracing and implementing the WHO cervical cancer elimination campaign goals: A consensus statement by SGO, ACOG, ASCCP, ASTRO, and ABS on minimum quality care standards for cervical cancer patients in the U.SKatherine Marie Ogden Martino et al. · Gynecologic Oncology · 2025 · PubMed · cited 8
- Dose finding, bioavailability, and PK-PD of oral triapine with concurrent chemoradiation for locally advanced cervical cancer and vaginal cancer (ETCTN 9892)Sarah Elizabeth Taylor et al. · Cancer Chemotherapy and Pharmacology · 2024 · PubMed · cited 7
- Association Between Metformin Use in Early Gestational or Type 2 Diabetes in Pregnancy and Preterm PreeclampsiaMaya Patel et al. · Obstetrics and Gynecology · 2024 · PubMed · cited 7